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ABSTRACT
Here, we used a data-mining and informatics approach to discover new 
biomarkers of resistance to hormonal therapy in breast cancer. More specifically, 
we investigated whether nuclear-encoded genes associated with mitochondrial 
biogenesis can be used to predict tumor recurrence, distant metastasis and treatment 
failure in high-risk breast cancer patients. Overall, this strategy allowed us to directly 
provide in silico validation of the prognostic value of these mitochondrial components 
in large and clinically relevant patient populations, with >15 years of follow-up data. 
For this purpose, we employed a group of 145 ER(+) luminal A breast cancer patients, 
with lymph-node (LN) metastasis at diagnosis, that were treated with tamoxifen, but 
not any chemotherapy agents. Using this approach, we identified >60 new individual 
mitochondrial biomarkers that predicted treatment failure and tumor recurrence, with 
hazard-ratios (HR) of up to 4.17 (p=2.2e-07). These include mitochondrial chaperones 
(HSPD1, HSPA9), membrane proteins (VDAC2, TOMM70A) and anti-oxidants (SOD2), 
as well as 18 different mitochondrial ribosomal proteins (MRPs) and >20 distinct 
components of the OXPHOS complexes. In addition, we combined 4 mitochondrial 
proteins (HSPD1, UQCRB, MRPL15, COX17), to generate a compact mitochondrial gene 
signature, associated with a HR of 5.34 (p=1e-09). This signature also successfully 
predicted distant metastasis and was effective in larger groups of ER(+) (N=2,447), 
basal (N=540) and HER2(+) (N=193) breast cancers. It was also effective in all breast 
cancers (N=3,180), if considered together as a single group. Based on this analysis, 
we conclude that mitochondrial biogenesis should be considered as a new therapeutic 
target for overcoming tumor recurrence, distant metastasis and treatment failure 
in patients with breast cancer. In summary, we identified individual mitochondrial 
biomarkers and 2 compact mitochondrial gene signatures that can be used to predict 
tamoxifen-resistance and tumor recurrence, at their initial diagnosis, in patients with 
advanced breast cancer. In the long-term, these mitochondrial biomarkers could 
provide a new companion diagnostics platform to help clinicians to accurately predict 
the response to hormonal therapy in ER(+) breast cancer patients, facilitating more 
personalized and effective treatment. Similarly, these mitochondrial markers could 
be used as companion diagnostics, to determine which breast cancer patients would 
benefit most from clinical treatments with mitochondrially-targeted anti-cancer 
therapeutics. Finally, we also showed that these mitochondrial  markers are superior 
when directly compared with conventional biomarkers, such as Ki67 and PCNA. 
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INTRODUCTION
Treatment failure, due to drug resistance, still 
remains a major obstacle for more effective anti-cancer 
therapy and personalized medicine [1-9]. In estrogen-
receptor-positive (ER(+)) breast cancer, approximately 
40-to-50% of patients eventually develop tamoxifen-
resistance [5-9]. Importantly, the five-year survival rate 
following tamoxifen-resistance is less than 20% [1-5]. 
Unfortunately, tamoxifen-resistance often manifests itself 
as tumor recurrence and/or distant metastasis. As such, 
resistance to endocrine therapy is a critical factor that still 
limits the efficacy of breast cancer treatment. Thus, better 
biomarkers and companion diagnostics are needed for the 
early detection of patients that will likely fail hormonal 
therapy [5-9].
Here, we set out to test the hypothesis that individual 
markers of mitochondrial biogenesis and OXPHOS 
may have prognostic value in the early identification 
of tamoxifen-resistant patients at diagnosis, up to 15 
years before the onset of tumor recurrence and distant 
metastasis. For this purpose, we performed outcome 
analysis on > 400 nuclear mitochondrial gene transcripts. 
Our results indicate that > 60 different mitochondrial 
markers can be used individually or in combination, as 
short signatures, to predict tumor recurrence in tamoxifen-
treated breast cancer patients. As a consequence, we 
discuss the possibility that mitochondria should be 
therapeutically targeted, to overcome resistance to 
hormonal therapy, and to prevent tumor recurrence and 
distant metastasis. In accordance with this idea, metformin 
(a mitochondrial complex I inhibitor) has been previously 
shown to overcome tamoxifen-resistance in ER(+) cell 
culture models, which mimic the tumor microenvironment 
by the addition of stromal fibroblasts [9-11]. 
Interestingly, mitochondrial markers also showed 
prognostic value in different sub-groups of ER(-) breast 
cancer patients [12]. 
RESULTS
Establishing the prognostic value of conventional 
markers in the patient population
To identify new potential biomarkers of 
tamoxifen-resistance, here we used publically available 
transcriptional profiling data from the tumors of breast 
cancer patients that were treated with tamoxifen, but 
did not receive any chemotherapy. For this purpose, we 
selected high-risk patients that were lymph-node positive 
at diagnosis, and we focused on the luminal A subtype, 
which represents the most common form of ER(+) breast 
cancers (N = 145 patients) (Figure 1). 
As proliferative markers are often used as the 
primary endpoint in clinical trials, we first assessed the 
prognostic value of Ki67 and PCNA, in this patient 
population. Table 1 and Figure 2A both show the 
Figure 1: Flow-diagram illustrating our overall informatics approach to breast cancer biomarker discovery for 
predicting tamoxifen-resistance. For this analysis, we chose to focus on ER(+) patients, luminal A sub-type, that were lymph-node 
positive (LN(+)) at diagnosis, who were treated with tamoxifen and followed over a period of nearly 200 months ( > 15 years). In this 
context, we evaluated the prognostic value of mitochondrial markers for predicting tumor recurrence or distant metastasis (treatment 
failure), as well as overall survival, in this patient population. 
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Figure 2: Conventional markers of proliferation and estrogen-receptor-alpha signaling predict clinical outcome in 
high-risk ER(+) breast cancer patients. We assessed the predictive value of Ki67 and PCNA in N = 145 ER(+) breast cancer 
patients, luminal A sub-type, that were lymph-node positive (LN(+)) at diagnosis, who were treated with tamoxifen and followed over a 
period of nearly 200 months ( > 15 years). A. Note that high transcript levels of Ki67 and PCNA are associated with increased levels of 
tumor recurrence, indicative of tamoxifen-resistance. Please note that the official gene name for the Ki67 protein is MKI67. B. Note that 
high transcript levels of estrogen-receptor (ESR1) and cyclin D1 expression (CCND1) are both associated with reduced tumor recurrence, 
showing increased efficacy of tamoxifen therapy. RFS, recurrence or relapse free survival is shown (a.k.a., tumor recurrence).
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prognostic value of these markers. The hazard-ratios 
for Ki67 and PCNA were 2.5 and 1.8, respectively, for 
relapse-free survival (RFS) (i.e., tumor recurrence). 
Next, we assessed the behavior of markers of 
estrogen receptor signaling in these patients. It would be 
predicted that increased levels of such markers would be 
associated with a positive response to hormonal therapy. 
As predicted, Table 2 and Figure 2B show that estrogen 
receptor-alpha (ESR1) and cyclin D1/2 levels (CCND1/2) 
both effectively predict tamoxifen-sensitivity, as reflected 
by a reduction in tumor recurrence. 
Finally, we also assessed the prognostic value of two 
macrophage-specific markers of inflammation. Table 3 
and Figure 3 show that CD68 and CD163 both effectively 
predict tumor recurrence, with hazard-ratios of 1.76 and 
2.95, respectively. 
Thus, conventional markers of proliferation, 
estrogen signaling, and inflammation can all be used to 
predict tumor-recurrence and tamoxifen-resistance in 
LN(+) luminal A breast cancer patients. 
Prognostic value of individual markers of 
mitochondrial biogenesis
To test our hypothesis that increased mitochondrial 
biogenesis contributes towards tumor recurrence and 
tamoxifen-resistance, we next assessed the prognostic 
value of specific mitochondrial markers. 
First, we examined the behavior of mitochondrial 
chaperones (HSPs) and mitochondrial membrane proteins 
(TIMM/TOMM/VDAC families). Table 4 and Figure 
4 show that HSP60 (HSPD1) and VDAC2 have the 
best prognostic value with hazard-ratios of 3.6 and 4.2, 
respectively. Importantly, several members of the TIMM 
and TOMM gene families also had prognostic value (HR = 
1.8-to-2.8). AKAP1 and IMMT also had significant value 
(HR = 1.8-to-2.2). Notably, the mitochondrial anti-oxidant 
SOD2 also showed significant prognostic value, with a 
hazard-ratio of 2.94 (p = 0.0001) (Table 4). Similar results 
were obtained with mitochondrial creatine kinase isoforms 
(HR = 2.0-to-2.2).
Figure 3: Conventional markers of macrophage-associated inflammation predict poor clinical outcome in high-risk 
ER(+) breast cancer patients. Note that that high transcript levels of CD163 and CD68 are associated with increased levels of tumor 
recurrence and, therefore, tamoxifen-resistance. 
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Next, we examined the prognostic value of all the 
known mitochondrial ribosomal proteins (MRPs), which 
contribute to the protein translation of key members of 
the OXPHOS-related complexes, and are essential for 
mitochondrial biogenesis (summarized in Table 5). 
Twelve different components of the large subunit 
(MRPLs) showed significant prognostic value, with 
hazard-ratios between 1.8 and 3.3. Most notably, MRPL15 
had the best prognostic value (HR = 3.3; p = 1.6e-05). 
Similarly, six different components of the small subunit 
(MRPSs) showed significant prognostic value, with 
hazard-ratios between 1.8 and 2.35. 
Thus, 18 different MRPs all predicted tumor 
recurrence. Kaplan-Meier curves for representative 
examples are shown in Figure 5, panels A & B.
We also assessed the prognostic value of members 
of the OXPHOS complexes I-V. These results are 
summarized in Table 6. Remarkably, greater than 20 
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Figure 5: Mitochondrial ribosomal proteins (MRPs) are associated with tumor recurrence in high-risk ER(+) breast 
cancer patients. A. Note that high transcript levels of MRPL15 and MRPL18 predict increased tumor recurrence and tamoxifen-
resistance. B. Similarly, high transcript levels of MRPS12 and MRPS11 predict increased tumor recurrence and tamoxifen-resistance.
Figure 4: Mitochondrial chaperones and membrane proteins are associated with tumor recurrence in high-risk ER(+) 
breast cancer patients. Note that that high transcript levels of HSPD1 and VDAC2 are associated with increased levels of tumor 
recurrence and resistance to hormonal therapy. 
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Figure 7: Mitochondrial complex IV and complex V proteins are associated with tumor recurrence in high-risk ER(+) 
breast cancer patients. A. Note that high levels of COX17 and COX5B predict increased tumor recurrence and tamoxifen-resistance. 
B. Similarly, high levels of ATP5J and ATP5J2 predict increased tumor recurrence and tamoxifen-resistance. 
Figure 6: Mitochondrial complex I and complex III proteins are associated with tumor recurrence in high-risk ER(+) 
breast cancer patients. A. Note that high levels of NDUFA8 and NDUFA6 predict increased tumor recurrence and tamoxifen-resistance. 
B. Similarly, high levels of UQCRB and UQCR6 predict increased tumor recurrence and tamoxifen-resistance. 
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Figure 8: A short mitochondrial signature (Mito-Signature-1) predicts poor clinical outcome in high-risk ER(+) breast 
cancer patients. Note that this short 4-gene signature (HSPD1/UQCRB/MRPL15/COX17) effectively predicts tumor recurrence and 
distant metastasis in LN(+) luminal A patients treated with tamoxifen therapy, indicative of treatment failure and tamoxifen-resistance. 
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different members of the OXPHOS complexes showed 
hazard-ratios between 1.9 and 3.4. UQCRB (complex 
III) had the best prognostic value (HR = 3.42; p = 1.9e-
05). Similarly, COX17 (complex IV) showed significant 
prognostic value (HR = 2.99; p = 7.6e-05). 
Kaplan-Meier curves for members of complex I 
and III are shown in Figure 6A & B, while results with 
members of complex IV and V are also shown in Figure 
7A & 7B.
Two new mitochondrial gene signatures for 
predicting tumor recurrence, distant metastasis 
and tamoxifen-resistance
In order to increase the prognostic power of these 
individual mitochondrial biomarkers, we next selected 
the most promising ones and used them to create two 
new mitochondrial gene signatures. Mito-Signature-1 
contains 4 genes (HSPD1, UQCRB, MRPL15, COX17), 
while Mito-Signature-2 consists of only 2 genes (HSPD1, 
VDAC2) (See Tables 7 & 8). K-M curves for these two 
signatures are shown in Figures 8 and 9.
Importantly, Mito-Signature-1 yielded a significantly 
improved hazard-ratio for tumor recurrence of 5.34 (p = 
1e-09). It was also highly predictive for distant metastasis, 
in the same group of patients (HR = 3.65; p = 4.9e-05).
Similarly, Mito-Signature-2 showed a hazard-ratio 
for tumor recurrence of 5.2 (p = 6e-09). Mito-Signature-2 
was also highly predictive for distant metastasis (HR = 
3.88; p = 6.8e-05).
Thus, both mitochondrial signatures were a 
significant improvement over individual mitochondrial 
biomarkers, as well as Ki67, PCNA, ESR1, CCND1/2 and 
CD68/CD163 (compare with Figures 2 & 3).
Figure 9: A short mitochondrial signature (Mito-Signature-2) predicts poor clinical outcome in high-risk ER(+) breast 
cancer patients. Note that this short 2-gene signature (HSPD1/VDAC2) effectively predicts tumor recurrence and distant metastasis in 
LN(+) luminal A patients treated with tamoxifen therapy, indicative of treatment failure and tamoxifen-resistance.
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Figure 10: Mitochondrial signatures 1 and 2 both have predictive value in a larger group of ER(+) breast cancer 
patients, who were treated with hormonal therapy. These patients were not sub-divided into luminal A/B subgroups and were 
not sub-divided by lymph-node status. A. K-M analysis with Mito-Signatures 1 & 2, showing tumor recurrence. N = 698 patients. B. K-M 
analysis with Mito-Signatures 1 & 2, showing overall survival. N = 127 patients. C. K-M analysis with individual markers (HSPD1 and 
VDAC2) is also shown for comparison. N = 698 patients. 
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Figure 12: K-M analysis with conventional proliferative markers, in the same patient population, is shown for 
comparison. Note that Mito Signature 1 & 2 show better predictive value than both proliferative markers, namely KI67 and PCNA. A. 
K-M analysis with KI67 is shown for both groups: LN(+) (N = 221 patients) and LN(-) (N = 403 patients). B. K-M analysis with PCNA is 
shown for both groups: LN(+) (N = 221 patients) and LN(-) (N = 403 patients).
Figure 11: Mitochondrial signatures 1 and 2 both have predictive value in a larger group of ER(+) breast cancer 
patients, who were treated with hormonal therapy. These patients were not sub-divided into luminal A/B subgroups, but were 
sub-divided by lymph-node status (LN(+) versus LN(-)). A. K-M analysis with Mito-Signature-1 is shown for both groups: LN(+) (N = 
221 patients) and LN(-) (N = 403 patients). B. K-M analysis with Mito-Signature-2 is shown for both groups: LN(+) (N = 221 patients) and 
LN(-) (N = 403 patients).
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Two short mitochondrial gene signatures can 
effectively predict tumor recurrence in larger 
ER(+) patient populations that received hormonal 
therapy, as well as in ER(-) patients, and all breast 
cancers, considered as a single group
We also examined the prognostic value of these two 
mitochondrial gene signatures in a larger group of ER(+) 
patients (N = 698), that received hormonal therapy, but not 
chemotherapy. This group of patients was not segregated 
into luminal A and luminal B subtypes. 
Figure 10A shows the results of this K-M analysis 
for relapse-free survival: Mito-Signature-1 (HR = 2.65; 
p = 3.2e-11) and Mitosignature-2 (HR = 3.3; p = 1.1e-
16). Similar results were also obtained for overall survival 
(Figure 10B). 
Both of these mitochondrial signatures were also 
effective if the ER(+) patient population was divided 
into LN(+) and LN(-) groups (Figure 11A & 11B). In 
addition, both of these mitochondrial signatures were 
clearly superior to Ki67 and PCNA in this larger ER(+) 
patient population. However, Ki67 still showed prognostic 
value (Figure 12A), while PCNA had no prognostic value 
(Figure 12B). 
Finally, we assessed the behavior of Mito-
Signature-1 in even larger and more varied patient 
populations, where the therapy was not restricted to 
tamoxifen. 
Supplemental Figure S1 shows that Mito-
Signature-1 was also effective in ER(+) (N = 2,447), ER-/
basal (N = 540), ER-/HER2(+) (N = 193), as well as in all 
breast cancer subtypes combined (N = 3,180). Similarly, 
Mito-Signature-1 was still statistically effective in both 
luminal A (N = 438 + 813) and luminal B (N = 907) 
patient populations (Supplemental Figure S2). Similarly, 
comparable results were obtained with Mito-Signature-2 
(data not shown).
Thus, these mitochondrial-based gene signatures 
may represent important new prognostic tools for 
predicting patient outcomes, in a wide variety of different 
breast cancer patients, but especially in ER(+) patients 
treated with hormonal therapies. 
DISCUSSION
Early detection of tamoxifen-resistance with 
mitochondrial markers: prevention of tumor 
recurrence and distant metastasis?
Here, we show that mitochondrial markers 
effectively predict tumor recurrence, distant metastasis 
and tamoxifen-resistance in high-risk ER(+) breast 
cancer patients. Importantly, these mitochondrial markers 
could now be used to identify high-risk ER(+) breast 
cancer patients at diagnosis, up to 15 years in advance, 
before they undergo tumor recurrence and metastasis. 
These results also suggest that mitochondria should 
be therapeutically-targeted in epithelial cancer cells to 
overcome tamoxifen-resistance and prevent the failure of 
hormonal therapy. 
Consistent with this hypothesis, we have previously 
shown that treatment with metformin (a mitochondrial 
complex I inhibitor) is indeed sufficient to reverse 
tamoxifen-resistance in fibroblast-MCF7 co-cultures 
[10, 11]. Thus, targeting mitochondrial biogenesis and 
OXPHOS in ER(+) epithelial breast cancer cells may be 
a new therapeutic strategy for preventing or reversing 
tamoxifen-resistance in breast cancer patients. 
Interestingly, these mitochondrial markers 
also showed predictive value in ER(-) breast cancer 
patients, both basal and HER2(+), suggesting that anti-
mitochondrial therapy could be used as a more general 
anti-cancer strategy, against several different breast cancer 
sub-types. 
A schematic diagram summarizing this new mito-
based approach is presented in Figure 13. In this workflow, 
high-risk patients are first identified at diagnosis by the 
high expression of mitochondrial markers in their primary 
breast tumors. Then, these patients would be treated with 
mitochondrial-based therapeutics (e.g., metformin or 
another FDA-approved drug; in combination with the 
standard of care), to help prevent tumor recurrence and 
distant metastasis. Alternatively, novel mitochondrial-
Figure 13: Mitochondrial-based Companion 
Diagnostics for Personalized Cancer Therapy. In this 
flow-diagram, mitochondrial-based diagnostics would be used 
to separate breast cancer patients into high-risk and low-risk 
groups. Then, patients with high levels of mitochondrial markers 
in their primary tumor (“bad prognosis”) would be treated with 
mitochondrial-based therapies (such as Metformin), as an add-
on to the standard of care, to prevent tumor recurrence, distant 
metastasis and tamoxifen-resistance. 
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based chemo-therapeutics could be developed against a 
variety of metabolic enzymes or structural proteins, to 
specifically target aggressive cancer cells with increased 
mitochondrial function. 
Evidence that mitochondrial power drives 
tamoxifen-resistance and cancer stem cell 
propagation
Consistent with the above hypothesis, we recently 
showed that tamoxifen-resistant MCF7 cells (TAMR) 
are characterized by a metabolic phenotype, consisting 
of i) increased mitochondrial biogenesis, ii) increased 
ATP production and iii) reduced glutathione levels [13]. 
Thus, inhibition of mitochondrial function may be a 
new therapeutic strategy for overcoming tamoxifen-
resistance in breast cancer patients. These findings 
could have important translational significance for the 
prevention of tumor recurrence in ER(+) breast cancers, 
which is due to an endocrine resistance phenotype [13]. 
Importantly, mitochondrial proteins may represent i) new 
prognostic biomarkers, ii) novel therapeutic targets and 
iii) companion diagnostics, for predicting and overcoming 
tamoxifen-resistance in different subsets of ER(+) breast 
cancer patients. 
Similarly, based on high-resolution proteomics 
analysis, we have also proposed that mitochondrial 
biogenesis is an important driver of the cancer stem cell 
(CSC) phenotype [14, 15]. A key correlate of this assertion 
is that high mitochondrial mass is a metabolic biomarker 
for CSCs. To directly test this idea experimentally, we used 
a fluorescent dye, known as MitoTracker, to detect and 
quantitate mitochondrial mass in ER(+) breast cancer cells 
(MCF7) [16]. Using this approach, we purified the Mito-
high and the Mito-low cell populations by flow cytometry 
(FACS). Remarkably, the Mito-high cell population 
was clearly enriched in cells with the characteristics of 
CSCs. Virtually identical results were also obtained with 
MDA-MB-231 cells, an ER(-) cell line. Thus, the use of 
“metabolic fractionation”, employing mitochondrial-based 
probes and flow cytometry, could be a successful new 
approach to the functional purification of drug-resistant 
CSCs. In accordance with this hypothesis, Mito-high 
breast cancer cells were also resistant to DNA-damage 
induced by Paclitaxel [16]. Thus, mitochondrial mass 
and function are directly linked to i) the CSC phenotype 
and ii) chemotherapeutic drug resistance, as well as iii) 
resistance to anti-estrogen therapy [13-24]. As such, we 
conclude that the association we observed here of high 
levels of mitochondrial markers (mRNA species and/or 
protein products) with poor clinical outcome in breast 
cancer patients may functionally reflect the presence of 
drug-resistant CSCs, driving tumor recurrence, metastasis 
and treatment failure. 
Using mitochondrial markers as companion 
diagnostics for drug re-purposing, treatment 
stratification and new drug discovery
Several classes of FDA-approved antibiotics 
safely inhibit either mitochondrial biogenesis or 
OXPHOS as off-target “side-effects”. These include 
the tetracyclines (doxycycline), the erythromycins 
(azithromycin), pyrvinium pamoate, atovaquone, and 
bedaquiline, among others [13-24]. Therefore, the new 
mitochondrial biomarkers that we identified here could 
be used in combination with these FDA-approved drugs, 
as companion diagnostics. This would allow clinicians 
to select the right patient populations for new clinical 
trials aimed at drug re-purposing/re-positioning, for the 
prevention of tumor recurrence in ER(+) patients receiving 
anti-endocrine therapy. 
Importantly, the novel mitochondrial biomarkers 
that we identified here may also be new therapeutic 
targets for future drug development aimed at combating 
the emergence of resistance to hormonal therapy. Based 
on our K-M analysis, the mitochondrial ribosome 
(a.k.a., mitoribosome) and its individual subunits 
would be attractive targets for intervention; in addition, 
mitochondrial chaperones, the OXPHOS complexes (I-
IV) and the mitochondrial ATP-synthase (complex V) may 
also be tractable targets. Since several members of each 
of these multi-subunit complexes show prognostic value, 
this provides an indication that inactivation, or specific 
modulation, of the activity of each of these complexes 
may provide significant therapeutic benefits. Therapeutic 
targeting of these complexes would be expected to prevent 
tumor recurrence and distant metastasis, as well as confer 
tamoxifen-sensitivity, in ER(+) breast cancer patients. 
MATERIALS AND METHODS
Kaplan-Meier (K-M) analyses
To perform K-M analysis on > 400 nuclear 
mitochondrial gene transcripts, we used an open-access 
online survival analysis tool to interrogate publically 
available microarray data from up to 3,455 breast 
cancer patients [12]. This allowed us to determine their 
prognostic value. For this purpose, we primarily analyzed 
data from ER(+) patients that were LN(+) at diagnosis 
and were of the luminal A sub-type, that were primarily 
treated with tamoxifen and not other chemotherapy (N = 
145 patients). In this group, 100% the patients received 
some form of hormonal therapy and ~95% of them 
received tamoxifen. Biased and outlier array data were 
excluded from the analysis. This allowed us to identify > 
60 nuclear mitochondrial gene transcripts, with significant 
prognostic value. Hazard-ratios were calculated, at the best 
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auto-selected cut-off, and p-values were calculated using 
the logrank test and plotted in R. K-M curves were also 
generated online using the K-M-plotter (as high-resolution 
TIFF files), using univariate analysis:
http://kmplot.com/analysis/index.php?p = 
service&cancer = breast
This allowed us to directly perform in silico 
validation of these mitochondrial biomarker candidates. 
The multi-gene classifier function of the program was 
used to test the prognostic value of short mitochondrial 
gene signatures, using the mean expression of the selected 
probes. The 2012 version of the database was originally 
utilized for all these analyses, because a higher percentage 
of the patients used tamoxifen; however, virtually identical 
results were also obtained with the 2014 and 2017 
versions.
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